The Deal: Progenics, Lantheus to Merge Amid Consent Solicitation

October 02, 2019

O’Melveny represented Progenics Pharmaceuticals Inc. in its sale to Lantheus Holdings, Inc., as reported in this article.

The transaction has been unanimously approved by the boards of directors of both companies. Under the terms of the agreement, Lantheus Holdings will acquire all of the issued and outstanding common shares of Progenics stock at a fixed exchange ratio.

To read the full article, click here.